Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne
- Research works
- 9 ▲ 5% vs 2013–17
- Citations
- 296 34.5 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 77% world 28%
Not ranked overall: Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which research topics does Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne publish most on?
By volume in 2022–2025: Protein Degradation and Inhibitors, Biomedical Ethics and Regulation, Acute Myeloid Leukemia Research and Immunodeficiency and Autoimmune Disorders.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Protein Degradation and Inhibitors Molecular Biology 0 works
- 2 Biomedical Ethics and Regulation Physiology 0 works
- 3 Acute Myeloid Leukemia Research Hematology 0 works
- 4 Immunodeficiency and Autoimmune Disorders Immunology 0 works
- 5 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 6 Platelet Disorders and Treatments Hematology 0 works
- 7 Hematological disorders and diagnostics Emergency Medicine 0 works
- 8 Immune cells in cancer Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne's research output changed?
Output in 2018–2022 was 5% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Villejuif
- Prédicteurs moléculaires et nouvelles cibles en oncologie
- Physiopathogénèse et Traitement des Maladies du Foie
- Radiothérapie Moléculaire et Innovation Thérapeutique
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.